ZA200100455B - Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. - Google Patents
Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. Download PDFInfo
- Publication number
- ZA200100455B ZA200100455B ZA200100455A ZA200100455A ZA200100455B ZA 200100455 B ZA200100455 B ZA 200100455B ZA 200100455 A ZA200100455 A ZA 200100455A ZA 200100455 A ZA200100455 A ZA 200100455A ZA 200100455 B ZA200100455 B ZA 200100455B
- Authority
- ZA
- South Africa
- Prior art keywords
- sulfonylamino
- tetrahydro
- dibenzofuran
- composition
- substance
- Prior art date
Links
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title claims description 11
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title claims description 11
- 239000003112 inhibitor Substances 0.000 title description 10
- 229940124530 sulfonamide Drugs 0.000 title description 4
- 150000003456 sulfonamides Chemical class 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 81
- 150000001875 compounds Chemical class 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 64
- 239000002552 dosage form Substances 0.000 claims description 31
- -1 alkanoylaminoalkyl Chemical group 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 claims description 13
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 9
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 239000004305 biphenyl Substances 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 230000001419 dependent effect Effects 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 206010019196 Head injury Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 125000003282 alkyl amino group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 208000030507 AIDS Diseases 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 5
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000024777 Prion disease Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
- 230000001363 autoimmune Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000010339 dilation Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 230000009545 invasion Effects 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 230000036407 pain Effects 0.000 claims description 5
- 208000028169 periodontal disease Diseases 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 230000002861 ventricular Effects 0.000 claims description 5
- 102100030416 Stromelysin-1 Human genes 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 4
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000004687 alkyl sulfinyl alkyl group Chemical group 0.000 claims description 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 70
- 239000000126 substance Substances 0.000 claims 68
- 230000002401 inhibitory effect Effects 0.000 claims 18
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 4
- 102000017284 Collagenase 3 Human genes 0.000 claims 3
- 208000007474 aortic aneurysm Diseases 0.000 claims 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- OBLRWMVIANNBJN-OAHLLOKOSA-N (2r)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propanoic acid Chemical compound O=C1C(C)(C)N(C)C(=O)N1C[C@H](C(O)=O)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 OBLRWMVIANNBJN-OAHLLOKOSA-N 0.000 claims 1
- IZDDCYCTFAGOON-MRXNPFEDSA-N (2r)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoic acid Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC[C@H](C(O)=O)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 IZDDCYCTFAGOON-MRXNPFEDSA-N 0.000 claims 1
- AHMKTRZVXNURCT-QGZVFWFLSA-N (2r)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-5-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)pentanoic acid Chemical compound O=C1C(C)(C)N(C)C(=O)N1CCC[C@H](C(O)=O)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 AHMKTRZVXNURCT-QGZVFWFLSA-N 0.000 claims 1
- PIACOSNINDXKNU-GFCCVEGCSA-N (2r)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanedioic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](CC(=O)O)C(O)=O)C=C1O2 PIACOSNINDXKNU-GFCCVEGCSA-N 0.000 claims 1
- HZNKKTKQHAFAON-GOSISDBHSA-N (2r)-3-(1,3-dioxoisoindol-2-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)O)CN1C(=O)C2=CC=CC=C2C1=O HZNKKTKQHAFAON-GOSISDBHSA-N 0.000 claims 1
- VLYHDTAMTOVJOV-GOSISDBHSA-N (2r)-3-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)NO)CN1C(=O)C2=CC=CC=C2C1=O VLYHDTAMTOVJOV-GOSISDBHSA-N 0.000 claims 1
- RQOMZODPDMUHQB-QGZVFWFLSA-N (2r)-3-methyl-2-(6,7,8,9-tetrahydro-5h-fluoren-2-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1CC1=CC(S(=O)(=O)N[C@H](C(C)C)C(O)=O)=CC=C12 RQOMZODPDMUHQB-QGZVFWFLSA-N 0.000 claims 1
- KTOYYHAFUWMZLO-MRXNPFEDSA-N (2r)-3-methyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](C(C)C)C(O)=O)C=C1O2 KTOYYHAFUWMZLO-MRXNPFEDSA-N 0.000 claims 1
- CAARDUCPOPELJI-MRXNPFEDSA-N (2r)-3-methyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](C(C)C)C(O)=O)C=C1S2 CAARDUCPOPELJI-MRXNPFEDSA-N 0.000 claims 1
- CWOHMEXCTHTDML-QGZVFWFLSA-N (2r)-3-methyl-2-(7,8,9,10-tetrahydro-6h-cyclohepta[b][1]benzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](C(C)C)C(O)=O)C=C1O2 CWOHMEXCTHTDML-QGZVFWFLSA-N 0.000 claims 1
- OMKDHUQPMKWAGD-QGZVFWFLSA-N (2r)-3-methyl-2-[(9-methyl-5,6,7,8-tetrahydrocarbazol-2-yl)sulfonylamino]butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](C(C)C)C(O)=O)C=C1N2C OMKDHUQPMKWAGD-QGZVFWFLSA-N 0.000 claims 1
- GRDZDVTXXIXWOZ-LJQANCHMSA-N (2r)-4-(1,3-dioxoisoindol-2-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)O)CCN1C(=O)C2=CC=CC=C2C1=O GRDZDVTXXIXWOZ-LJQANCHMSA-N 0.000 claims 1
- BTJHNUKTLLRZGB-LJQANCHMSA-N (2r)-4-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)NO)CCN1C(=O)C2=CC=CC=C2C1=O BTJHNUKTLLRZGB-LJQANCHMSA-N 0.000 claims 1
- CAEWMNQQSJLRTO-OAQYLSRUSA-N (2r)-4-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)O)CCC1=CNC2=CC=CC=C12 CAEWMNQQSJLRTO-OAQYLSRUSA-N 0.000 claims 1
- HNEFGOMOYFKACW-LJQANCHMSA-N (2r)-4-(phenylsulfamoyl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)NC1=CC=CC=C1 HNEFGOMOYFKACW-LJQANCHMSA-N 0.000 claims 1
- IDZXKDMOCMXAPR-HXUWFJFHSA-N (2r)-4-benzylsulfanyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CSCC1=CC=CC=C1 IDZXKDMOCMXAPR-HXUWFJFHSA-N 0.000 claims 1
- WQTGBJAPYVORGF-HXUWFJFHSA-N (2r)-4-benzylsulfanyl-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CSCC1=CC=CC=C1 WQTGBJAPYVORGF-HXUWFJFHSA-N 0.000 claims 1
- RVULEVASPFLHLV-DXHYANOHSA-N (2r)-4-benzylsulfinyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)CC1=CC=CC=C1 RVULEVASPFLHLV-DXHYANOHSA-N 0.000 claims 1
- FUMIHMIALNSWIR-FTHRPBJHSA-N (2r)-4-benzylsulfinyl-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)CC1=CC=CC=C1 FUMIHMIALNSWIR-FTHRPBJHSA-N 0.000 claims 1
- WNYPNJGYOHRJDD-HXUWFJFHSA-N (2r)-4-benzylsulfonyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)CC1=CC=CC=C1 WNYPNJGYOHRJDD-HXUWFJFHSA-N 0.000 claims 1
- ZIJFJSXEVTZTCV-HXUWFJFHSA-N (2r)-4-benzylsulfonyl-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)CC1=CC=CC=C1 ZIJFJSXEVTZTCV-HXUWFJFHSA-N 0.000 claims 1
- XQQJAHROIBOIEN-LJQANCHMSA-N (2r)-4-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 XQQJAHROIBOIEN-LJQANCHMSA-N 0.000 claims 1
- UGVMTJLJRFCSBG-LJQANCHMSA-N (2r)-4-phenyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2SC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 UGVMTJLJRFCSBG-LJQANCHMSA-N 0.000 claims 1
- FUMCSHVGHRBUQI-HXUWFJFHSA-N (2r)-5-(1,3-dioxoisoindol-2-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)O)CCCN1C(=O)C2=CC=CC=C2C1=O FUMCSHVGHRBUQI-HXUWFJFHSA-N 0.000 claims 1
- RURBVYFVVRWLNK-HXUWFJFHSA-N (2r)-5-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCC1=CC=CC=C1 RURBVYFVVRWLNK-HXUWFJFHSA-N 0.000 claims 1
- PYOINNFLBULGRA-HSZRJFAPSA-N (2r)-6-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)O)CCCCC1=CNC2=CC=CC=C12 PYOINNFLBULGRA-HSZRJFAPSA-N 0.000 claims 1
- MLBBPXVRDNIHJC-OAQYLSRUSA-N (2r)-6-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCC1=CC=CC=C1 MLBBPXVRDNIHJC-OAQYLSRUSA-N 0.000 claims 1
- NFBUUTBIBAVKLD-JOCHJYFZSA-N (2r)-7-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)heptanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCC1=CC=CC=C1 NFBUUTBIBAVKLD-JOCHJYFZSA-N 0.000 claims 1
- HBIKHOSCZRWSEL-RUZDIDTESA-N (2r)-8-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)O)CCCCCCC1=CNC2=CC=CC=C12 HBIKHOSCZRWSEL-RUZDIDTESA-N 0.000 claims 1
- XJQNTOUGNJLTEI-HSZRJFAPSA-N (2r)-8-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanoic acid Chemical compound C([C@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCCC1=CC=CC=C1 XJQNTOUGNJLTEI-HSZRJFAPSA-N 0.000 claims 1
- AFKSZKIAONISER-OAHLLOKOSA-N (2r)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propanamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1C[C@H](C(=O)NO)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 AFKSZKIAONISER-OAHLLOKOSA-N 0.000 claims 1
- VHGYSBTUWJGSRF-QGZVFWFLSA-N (2r)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-5-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)pentanamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CCC[C@H](C(=O)NO)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 VHGYSBTUWJGSRF-QGZVFWFLSA-N 0.000 claims 1
- LMLGIIFXEZBYQR-LJQANCHMSA-N (2r)-n-hydroxy-2-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)acetamide Chemical compound C1([C@@H](NS(=O)(=O)C=2C=C3OC=4CCCCC=4C3=CC=2)C(=O)NO)=CC=CC=C1 LMLGIIFXEZBYQR-LJQANCHMSA-N 0.000 claims 1
- DMHKCYMLAUKROF-HXUWFJFHSA-N (2r)-n-hydroxy-3-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)NO)CC1=CNC2=CC=CC=C12 DMHKCYMLAUKROF-HXUWFJFHSA-N 0.000 claims 1
- RSZXSYOEVCQTMZ-QGZVFWFLSA-N (2r)-n-hydroxy-3-methyl-2-(6,7,8,9-tetrahydro-5h-fluoren-2-ylsulfonylamino)butanamide Chemical compound C1CCCC2=C1CC1=CC(S(=O)(=O)N[C@H](C(C)C)C(=O)NO)=CC=C12 RSZXSYOEVCQTMZ-QGZVFWFLSA-N 0.000 claims 1
- PHTUCILVJHAFRI-MRXNPFEDSA-N (2r)-n-hydroxy-3-methyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](C(C)C)C(=O)NO)C=C1O2 PHTUCILVJHAFRI-MRXNPFEDSA-N 0.000 claims 1
- BZQWQTZPEKNVFG-MRXNPFEDSA-N (2r)-n-hydroxy-3-methyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanamide Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](C(C)C)C(=O)NO)C=C1S2 BZQWQTZPEKNVFG-MRXNPFEDSA-N 0.000 claims 1
- SFBFEJANKUXLMO-OAQYLSRUSA-N (2r)-n-hydroxy-4-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)NO)CCC1=CNC2=CC=CC=C12 SFBFEJANKUXLMO-OAQYLSRUSA-N 0.000 claims 1
- MSIJLLVHAOLDGD-LJQANCHMSA-N (2r)-n-hydroxy-4-(phenylsulfamoyl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)NC1=CC=CC=C1 MSIJLLVHAOLDGD-LJQANCHMSA-N 0.000 claims 1
- QZWWSEOQSWGBCT-JOCHJYFZSA-N (2r)-n-hydroxy-4-phenyl-2-(6,7,8,9-tetrahydro-5h-fluoren-2-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2CC3=C(CCCC3)C2=CC=1)CC1=CC=CC=C1 QZWWSEOQSWGBCT-JOCHJYFZSA-N 0.000 claims 1
- YIAJDZLMFYJENV-LJQANCHMSA-N (2r)-n-hydroxy-4-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 YIAJDZLMFYJENV-LJQANCHMSA-N 0.000 claims 1
- FNDCPICMMNEQGO-LJQANCHMSA-N (2r)-n-hydroxy-4-phenyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2SC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 FNDCPICMMNEQGO-LJQANCHMSA-N 0.000 claims 1
- XFFFSONVWXSQJR-HXUWFJFHSA-N (2r)-n-hydroxy-5-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCC1=CC=CC=C1 XFFFSONVWXSQJR-HXUWFJFHSA-N 0.000 claims 1
- MXGGULCZDAGEIR-HSZRJFAPSA-N (2r)-n-hydroxy-6-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@@H](C(=O)NO)CCCCC1=CNC2=CC=CC=C12 MXGGULCZDAGEIR-HSZRJFAPSA-N 0.000 claims 1
- QAWXUQHRVLWYIQ-OAQYLSRUSA-N (2r)-n-hydroxy-6-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCC1=CC=CC=C1 QAWXUQHRVLWYIQ-OAQYLSRUSA-N 0.000 claims 1
- FKKVCOCMAOHGMH-JOCHJYFZSA-N (2r)-n-hydroxy-7-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)heptanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCC1=CC=CC=C1 FKKVCOCMAOHGMH-JOCHJYFZSA-N 0.000 claims 1
- POSNPMBRLUAHBF-HSZRJFAPSA-N (2r)-n-hydroxy-8-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanamide Chemical compound C([C@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCCC1=CC=CC=C1 POSNPMBRLUAHBF-HSZRJFAPSA-N 0.000 claims 1
- OBLRWMVIANNBJN-HNNXBMFYSA-N (2s)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propanoic acid Chemical compound O=C1C(C)(C)N(C)C(=O)N1C[C@@H](C(O)=O)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 OBLRWMVIANNBJN-HNNXBMFYSA-N 0.000 claims 1
- IZDDCYCTFAGOON-INIZCTEOSA-N (2s)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoic acid Chemical compound O=C1C(C)(C)N(C)C(=O)N1CC[C@@H](C(O)=O)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 IZDDCYCTFAGOON-INIZCTEOSA-N 0.000 claims 1
- AHMKTRZVXNURCT-KRWDZBQOSA-N (2s)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-5-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)pentanoic acid Chemical compound O=C1C(C)(C)N(C)C(=O)N1CCC[C@@H](C(O)=O)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 AHMKTRZVXNURCT-KRWDZBQOSA-N 0.000 claims 1
- PIACOSNINDXKNU-LBPRGKRZSA-N (2s)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanedioic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](CC(=O)O)C(O)=O)C=C1O2 PIACOSNINDXKNU-LBPRGKRZSA-N 0.000 claims 1
- HZNKKTKQHAFAON-SFHVURJKSA-N (2s)-3-(1,3-dioxoisoindol-2-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CN1C(=O)C2=CC=CC=C2C1=O HZNKKTKQHAFAON-SFHVURJKSA-N 0.000 claims 1
- VLYHDTAMTOVJOV-SFHVURJKSA-N (2s)-3-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)NO)CN1C(=O)C2=CC=CC=C2C1=O VLYHDTAMTOVJOV-SFHVURJKSA-N 0.000 claims 1
- MNTISXAWZZNIAP-FQEVSTJZSA-N (2s)-3-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CC1=CNC2=CC=CC=C12 MNTISXAWZZNIAP-FQEVSTJZSA-N 0.000 claims 1
- RQOMZODPDMUHQB-KRWDZBQOSA-N (2s)-3-methyl-2-(6,7,8,9-tetrahydro-5h-fluoren-2-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1CC1=CC(S(=O)(=O)N[C@@H](C(C)C)C(O)=O)=CC=C12 RQOMZODPDMUHQB-KRWDZBQOSA-N 0.000 claims 1
- KTOYYHAFUWMZLO-INIZCTEOSA-N (2s)-3-methyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(O)=O)C=C1O2 KTOYYHAFUWMZLO-INIZCTEOSA-N 0.000 claims 1
- CAARDUCPOPELJI-INIZCTEOSA-N (2s)-3-methyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(O)=O)C=C1S2 CAARDUCPOPELJI-INIZCTEOSA-N 0.000 claims 1
- OMKDHUQPMKWAGD-KRWDZBQOSA-N (2s)-3-methyl-2-[(9-methyl-5,6,7,8-tetrahydrocarbazol-2-yl)sulfonylamino]butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(O)=O)C=C1N2C OMKDHUQPMKWAGD-KRWDZBQOSA-N 0.000 claims 1
- GRDZDVTXXIXWOZ-IBGZPJMESA-N (2s)-4-(1,3-dioxoisoindol-2-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CCN1C(=O)C2=CC=CC=C2C1=O GRDZDVTXXIXWOZ-IBGZPJMESA-N 0.000 claims 1
- BTJHNUKTLLRZGB-IBGZPJMESA-N (2s)-4-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)NO)CCN1C(=O)C2=CC=CC=C2C1=O BTJHNUKTLLRZGB-IBGZPJMESA-N 0.000 claims 1
- CAEWMNQQSJLRTO-NRFANRHFSA-N (2s)-4-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CCC1=CNC2=CC=CC=C12 CAEWMNQQSJLRTO-NRFANRHFSA-N 0.000 claims 1
- HNEFGOMOYFKACW-IBGZPJMESA-N (2s)-4-(phenylsulfamoyl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)NC1=CC=CC=C1 HNEFGOMOYFKACW-IBGZPJMESA-N 0.000 claims 1
- IDZXKDMOCMXAPR-FQEVSTJZSA-N (2s)-4-benzylsulfanyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CSCC1=CC=CC=C1 IDZXKDMOCMXAPR-FQEVSTJZSA-N 0.000 claims 1
- WQTGBJAPYVORGF-FQEVSTJZSA-N (2s)-4-benzylsulfanyl-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CSCC1=CC=CC=C1 WQTGBJAPYVORGF-FQEVSTJZSA-N 0.000 claims 1
- RVULEVASPFLHLV-MFYZJFEASA-N (2s)-4-benzylsulfinyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)CC1=CC=CC=C1 RVULEVASPFLHLV-MFYZJFEASA-N 0.000 claims 1
- WNYPNJGYOHRJDD-FQEVSTJZSA-N (2s)-4-benzylsulfonyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)CC1=CC=CC=C1 WNYPNJGYOHRJDD-FQEVSTJZSA-N 0.000 claims 1
- ZIJFJSXEVTZTCV-FQEVSTJZSA-N (2s)-4-benzylsulfonyl-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)CC1=CC=CC=C1 ZIJFJSXEVTZTCV-FQEVSTJZSA-N 0.000 claims 1
- XQQJAHROIBOIEN-IBGZPJMESA-N (2s)-4-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 XQQJAHROIBOIEN-IBGZPJMESA-N 0.000 claims 1
- UGVMTJLJRFCSBG-IBGZPJMESA-N (2s)-4-phenyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2SC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 UGVMTJLJRFCSBG-IBGZPJMESA-N 0.000 claims 1
- FUMCSHVGHRBUQI-FQEVSTJZSA-N (2s)-5-(1,3-dioxoisoindol-2-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CCCN1C(=O)C2=CC=CC=C2C1=O FUMCSHVGHRBUQI-FQEVSTJZSA-N 0.000 claims 1
- GERKHPZGXRXETN-FQEVSTJZSA-N (2s)-5-(1,3-dioxoisoindol-2-yl)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)NO)CCCN1C(=O)C2=CC=CC=C2C1=O GERKHPZGXRXETN-FQEVSTJZSA-N 0.000 claims 1
- RURBVYFVVRWLNK-FQEVSTJZSA-N (2s)-5-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCC1=CC=CC=C1 RURBVYFVVRWLNK-FQEVSTJZSA-N 0.000 claims 1
- PYOINNFLBULGRA-QHCPKHFHSA-N (2s)-6-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CCCCC1=CNC2=CC=CC=C12 PYOINNFLBULGRA-QHCPKHFHSA-N 0.000 claims 1
- MLBBPXVRDNIHJC-NRFANRHFSA-N (2s)-6-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCC1=CC=CC=C1 MLBBPXVRDNIHJC-NRFANRHFSA-N 0.000 claims 1
- KUYGCEVELYWCOQ-DEOSSOPVSA-N (2s)-7-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)heptanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CCCCCC1=CNC2=CC=CC=C12 KUYGCEVELYWCOQ-DEOSSOPVSA-N 0.000 claims 1
- NFBUUTBIBAVKLD-QFIPXVFZSA-N (2s)-7-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)heptanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCC1=CC=CC=C1 NFBUUTBIBAVKLD-QFIPXVFZSA-N 0.000 claims 1
- HBIKHOSCZRWSEL-VWLOTQADSA-N (2s)-8-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanoic acid Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)O)CCCCCCC1=CNC2=CC=CC=C12 HBIKHOSCZRWSEL-VWLOTQADSA-N 0.000 claims 1
- XJQNTOUGNJLTEI-QHCPKHFHSA-N (2s)-8-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanoic acid Chemical compound C([C@@H](C(=O)O)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCCC1=CC=CC=C1 XJQNTOUGNJLTEI-QHCPKHFHSA-N 0.000 claims 1
- AFKSZKIAONISER-HNNXBMFYSA-N (2s)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-3-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)propanamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1C[C@@H](C(=O)NO)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 AFKSZKIAONISER-HNNXBMFYSA-N 0.000 claims 1
- VHGYSBTUWJGSRF-KRWDZBQOSA-N (2s)-n-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)-5-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)pentanamide Chemical compound O=C1C(C)(C)N(C)C(=O)N1CCC[C@@H](C(=O)NO)NS(=O)(=O)C1=CC=C(C2=C(CCCC2)O2)C2=C1 VHGYSBTUWJGSRF-KRWDZBQOSA-N 0.000 claims 1
- LMLGIIFXEZBYQR-IBGZPJMESA-N (2s)-n-hydroxy-2-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)acetamide Chemical compound C1([C@H](NS(=O)(=O)C=2C=C3OC=4CCCCC=4C3=CC=2)C(=O)NO)=CC=CC=C1 LMLGIIFXEZBYQR-IBGZPJMESA-N 0.000 claims 1
- DMHKCYMLAUKROF-FQEVSTJZSA-N (2s)-n-hydroxy-3-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)propanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)NO)CC1=CNC2=CC=CC=C12 DMHKCYMLAUKROF-FQEVSTJZSA-N 0.000 claims 1
- PHTUCILVJHAFRI-INIZCTEOSA-N (2s)-n-hydroxy-3-methyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(=O)NO)C=C1O2 PHTUCILVJHAFRI-INIZCTEOSA-N 0.000 claims 1
- BZQWQTZPEKNVFG-INIZCTEOSA-N (2s)-n-hydroxy-3-methyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanamide Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(=O)NO)C=C1S2 BZQWQTZPEKNVFG-INIZCTEOSA-N 0.000 claims 1
- SQXKOAGDIFKMAF-KRWDZBQOSA-N (2s)-n-hydroxy-3-methyl-2-(7,8,9,10-tetrahydro-6h-cyclohepta[b][1]benzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(=O)NO)C=C1O2 SQXKOAGDIFKMAF-KRWDZBQOSA-N 0.000 claims 1
- PYUURZUOCYVISI-KRWDZBQOSA-N (2s)-n-hydroxy-3-methyl-2-[(9-methyl-5,6,7,8-tetrahydrocarbazol-2-yl)sulfonylamino]butanamide Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](C(C)C)C(=O)NO)C=C1N2C PYUURZUOCYVISI-KRWDZBQOSA-N 0.000 claims 1
- SFBFEJANKUXLMO-NRFANRHFSA-N (2s)-n-hydroxy-4-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)NO)CCC1=CNC2=CC=CC=C12 SFBFEJANKUXLMO-NRFANRHFSA-N 0.000 claims 1
- MSIJLLVHAOLDGD-IBGZPJMESA-N (2s)-n-hydroxy-4-(phenylsulfamoyl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CS(=O)(=O)NC1=CC=CC=C1 MSIJLLVHAOLDGD-IBGZPJMESA-N 0.000 claims 1
- YIAJDZLMFYJENV-IBGZPJMESA-N (2s)-n-hydroxy-4-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 YIAJDZLMFYJENV-IBGZPJMESA-N 0.000 claims 1
- FNDCPICMMNEQGO-IBGZPJMESA-N (2s)-n-hydroxy-4-phenyl-2-(6,7,8,9-tetrahydrodibenzothiophen-3-ylsulfonylamino)butanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2SC=3CCCCC=3C2=CC=1)CC1=CC=CC=C1 FNDCPICMMNEQGO-IBGZPJMESA-N 0.000 claims 1
- XFFFSONVWXSQJR-FQEVSTJZSA-N (2s)-n-hydroxy-5-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)pentanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCC1=CC=CC=C1 XFFFSONVWXSQJR-FQEVSTJZSA-N 0.000 claims 1
- QAWXUQHRVLWYIQ-NRFANRHFSA-N (2s)-n-hydroxy-6-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)hexanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCC1=CC=CC=C1 QAWXUQHRVLWYIQ-NRFANRHFSA-N 0.000 claims 1
- FKKVCOCMAOHGMH-QFIPXVFZSA-N (2s)-n-hydroxy-7-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)heptanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCC1=CC=CC=C1 FKKVCOCMAOHGMH-QFIPXVFZSA-N 0.000 claims 1
- ANWFOUUTHJPKJL-VWLOTQADSA-N (2s)-n-hydroxy-8-(1h-indol-3-yl)-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanamide Chemical compound C1CCCC(OC2=C3)=C1C2=CC=C3S(=O)(=O)N[C@H](C(=O)NO)CCCCCCC1=CNC2=CC=CC=C12 ANWFOUUTHJPKJL-VWLOTQADSA-N 0.000 claims 1
- POSNPMBRLUAHBF-QHCPKHFHSA-N (2s)-n-hydroxy-8-phenyl-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)octanamide Chemical compound C([C@@H](C(=O)NO)NS(=O)(=O)C=1C=C2OC=3CCCCC=3C2=CC=1)CCCCCC1=CC=CC=C1 POSNPMBRLUAHBF-QHCPKHFHSA-N 0.000 claims 1
- NPIPKUYPQOIUDY-GFCCVEGCSA-N (3r)-4-(hydroxyamino)-4-oxo-3-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@H](CC(O)=O)C(=O)NO)C=C1O2 NPIPKUYPQOIUDY-GFCCVEGCSA-N 0.000 claims 1
- NPIPKUYPQOIUDY-LBPRGKRZSA-N (3s)-4-(hydroxyamino)-4-oxo-3-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanoic acid Chemical compound C1CCCC2=C1C1=CC=C(S(=O)(=O)N[C@@H](CC(O)=O)C(=O)NO)C=C1O2 NPIPKUYPQOIUDY-LBPRGKRZSA-N 0.000 claims 1
- FUMIHMIALNSWIR-UHFFFAOYSA-N 4-benzylsulfinyl-N-hydroxy-2-(6,7,8,9-tetrahydrodibenzofuran-3-ylsulfonylamino)butanamide Chemical compound ONC(=O)C(CCS(=O)Cc1ccccc1)NS(=O)(=O)c1ccc2c3CCCCc3oc2c1 FUMIHMIALNSWIR-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000005741 Metalloproteases Human genes 0.000 description 6
- 108010006035 Metalloproteases Proteins 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 210000003584 mesangial cell Anatomy 0.000 description 6
- 102100027995 Collagenase 3 Human genes 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001434 glomerular Effects 0.000 description 4
- 210000000585 glomerular basement membrane Anatomy 0.000 description 4
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000003878 glomerular mesangial cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000037314 wound repair Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102000056189 Neutrophil collagenases Human genes 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 229910006069 SO3H Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 201000002491 encephalomyelitis Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000885 nephron Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical class ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000006032 3-methyl-3-butenyl group Chemical group 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 102000017304 72kDa type IV collagenases Human genes 0.000 description 1
- 108050005269 72kDa type IV collagenases Proteins 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000024985 Alport syndrome Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 description 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 1
- 206010021263 IgA nephropathy Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 229940124761 MMP inhibitor Drugs 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010076497 Matrix Metalloproteinase 10 Proteins 0.000 description 1
- 108010076502 Matrix Metalloproteinase 11 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 101000627863 Rattus norvegicus 72 kDa type IV collagenase Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 230000000963 caseinolytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000000477 gelanolytic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 208000003215 hereditary nephritis Diseases 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003774 sulfhydryl reagent Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/28—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal
- H04M15/30—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP with meter at substation or with calculation of charges at terminal the meter or calculation of charges not being controlled from an exchange
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/31—Distributed metering or calculation of charges
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/49—Connection to several service providers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/80—Rating or billing plans; Tariff determination aspects
- H04M15/8044—Least cost routing
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M15/00—Arrangements for metering, time-control or time indication ; Metering, charging or billing arrangements for voice wireline or wireless communications, e.g. VoIP
- H04M15/83—Notification aspects
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/01—Details of billing arrangements
- H04M2215/0168—On line or real-time flexible customization or negotiation according to wishes of subscriber
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/42—Least cost routing, i.e. provision for selecting the lowest cost tariff
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/46—Connection to several service providers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/74—Rating aspects, e.g. rating parameters or tariff determination apects
- H04M2215/745—Least cost routing, e.g. Automatic or manual, call by call or by preselection
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/82—Advice-of-Charge [AOC], i.e. notify subscriber of charges/cumulative charge; meter at the substation
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/92—Autonomous calculations of charges in terminal, i.e. meter not controlled from exchange
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04M—TELEPHONIC COMMUNICATION
- H04M2215/00—Metering arrangements; Time controlling arrangements; Time indicating arrangements
- H04M2215/96—Distributed calculation of charges, e.g. in different nodes like for mobiles between HLR and VLR, or between the terminal and the billing function
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Computer Networks & Wireless Communication (AREA)
- Signal Processing (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9500698P | 1998-07-30 | 1998-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200100455B true ZA200100455B (en) | 2002-01-16 |
Family
ID=22248526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200100455A ZA200100455B (en) | 1998-07-30 | 2001-01-16 | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6420408B1 (de) |
| EP (1) | EP1100792B1 (de) |
| JP (1) | JP2002521478A (de) |
| KR (1) | KR20010072089A (de) |
| CN (1) | CN1310716A (de) |
| AP (1) | AP2001002037A0 (de) |
| AT (1) | ATE261954T1 (de) |
| AU (1) | AU758619B2 (de) |
| BG (1) | BG105185A (de) |
| BR (1) | BR9912600A (de) |
| CA (1) | CA2335077A1 (de) |
| DE (1) | DE69915634T2 (de) |
| DK (1) | DK1100792T3 (de) |
| EA (1) | EA200100158A1 (de) |
| EE (1) | EE200100063A (de) |
| ES (1) | ES2216614T3 (de) |
| GE (1) | GEP20033052B (de) |
| HR (1) | HRP20010078A2 (de) |
| HU (1) | HUP0102714A3 (de) |
| ID (1) | ID27192A (de) |
| IL (1) | IL140746A0 (de) |
| IS (1) | IS5810A (de) |
| NO (1) | NO20010479D0 (de) |
| NZ (1) | NZ509439A (de) |
| OA (1) | OA11589A (de) |
| PL (1) | PL345776A1 (de) |
| PT (1) | PT1100792E (de) |
| SK (1) | SK1192001A3 (de) |
| TR (1) | TR200100239T2 (de) |
| WO (1) | WO2000006561A1 (de) |
| YU (1) | YU6701A (de) |
| ZA (1) | ZA200100455B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6846799B1 (en) | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| MXPA01013171A (es) * | 2001-02-14 | 2004-05-21 | Warner Lambert Co | Inhibidores triciclicos de sulfonamida de metaloproteinasa de matriz. |
| ATE515495T1 (de) * | 2001-08-03 | 2011-07-15 | Schering Corp | Gamma sekretase inhibitoren |
| EP1438036A2 (de) * | 2001-10-12 | 2004-07-21 | Eli Lilly And Company | Verwendung von sulfonamidderivaten als pharmazeutische verbindungen |
| RS51155B (sr) * | 2001-12-20 | 2010-10-31 | Bristol-Myers Squibb Company | DERIVATI α -(N-SULFONAMIDO)ACETAMIDA KAO INHIBITORI β -AMILOIDA |
| AU2003237518B8 (en) * | 2002-06-11 | 2009-03-12 | Arqule, Inc. | Substituted phenylsulfonamide inhibitors of beta amyloid production |
| CA2495432A1 (en) * | 2002-07-17 | 2004-01-22 | Warner-Lambert Company Llc | Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| US20050095267A1 (en) * | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US7524938B2 (en) | 2003-04-04 | 2009-04-28 | Yeda Research And Development Co., Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| ES2537514T3 (es) | 2003-04-04 | 2015-06-09 | Incyte Corporation | Composiciones, métodos y kits relacionados con la escisión de HER-2 |
| WO2005061448A1 (en) * | 2003-12-24 | 2005-07-07 | Monash University | Compositions and methods for treating vascular conditions |
| US20060112494A1 (en) * | 2004-12-01 | 2006-06-01 | David Oppong | Method of protecting an animal skin product from metalloproteinase activity |
| CA2678304A1 (en) | 2007-02-23 | 2008-08-28 | Yeda Research And Development Co. Ltd. | Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| US8012947B2 (en) * | 2007-03-15 | 2011-09-06 | Hospital For Special Surgery | Methods and compositions for promoting wound healing |
| US20090285840A1 (en) * | 2008-04-29 | 2009-11-19 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Methods for treating pathological neovascularization |
| CA2676946A1 (en) | 2009-08-28 | 2011-02-28 | Lucie Peduto | Adam12 inhibitors and their use against inflammation-induced fibrosis |
| CN103249719A (zh) | 2010-09-24 | 2013-08-14 | 兰贝克赛实验室有限公司 | 基质金属蛋白酶抑制剂 |
| WO2017134265A1 (en) | 2016-02-05 | 2017-08-10 | Institut Pasteur | Use of inhibitors of adam12 as adjuvants in tumor therapies |
| CN114981251B (zh) * | 2020-01-21 | 2023-11-21 | 深圳信立泰药业股份有限公司 | 一种二苯并呋喃类衍生物组织蛋白酶k抑制剂及其制备方法和医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH517064A (de) * | 1969-07-09 | 1971-12-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäurederivaten |
| CH531502A (de) * | 1970-03-20 | 1972-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Aryloxy- und Arylthioalkansäurealkylestern |
| PH31294A (en) * | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
| AU717570B2 (en) | 1995-06-02 | 2000-03-30 | Warner-Lambert Company | Tricyclic inhibitors of matrix metalloproteinases |
| US5883940A (en) | 1996-07-01 | 1999-03-16 | Teledynamics Group, Inc. | Interactive method and apparatus for the generation of leads |
| JP2000516607A (ja) | 1996-08-16 | 2000-12-12 | ワーナー―ランバート・コンパニー | 酪酸マトリックスメタロプロテイナーゼ阻害剤 |
| AU736347B2 (en) * | 1996-09-04 | 2001-07-26 | Warner-Lambert Company | Compounds for and a method of inhibiting matrix metalloproteinases |
| AU735013B2 (en) * | 1996-09-04 | 2001-06-28 | Warner-Lambert Company | Matrix metalloproteinase inhibitors and their therapeutic uses |
| NZ335028A (en) * | 1996-10-16 | 2000-09-29 | American Cyanamid Co | Ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase (MMP) and TACE (TNF-alpha converting enzyme) inhibitors |
-
1999
- 1999-06-02 HU HU0102714A patent/HUP0102714A3/hu unknown
- 1999-06-02 EP EP99963141A patent/EP1100792B1/de not_active Expired - Lifetime
- 1999-06-02 DE DE69915634T patent/DE69915634T2/de not_active Expired - Fee Related
- 1999-06-02 EA EA200100158A patent/EA200100158A1/ru unknown
- 1999-06-02 EE EEP200100063A patent/EE200100063A/xx unknown
- 1999-06-02 PT PT99963141T patent/PT1100792E/pt unknown
- 1999-06-02 CN CN99808838A patent/CN1310716A/zh active Pending
- 1999-06-02 TR TR2001/00239T patent/TR200100239T2/xx unknown
- 1999-06-02 BR BR9912600-1A patent/BR9912600A/pt not_active IP Right Cessation
- 1999-06-02 AP APAP/P/2001/002037A patent/AP2001002037A0/en unknown
- 1999-06-02 ES ES99963141T patent/ES2216614T3/es not_active Expired - Lifetime
- 1999-06-02 SK SK119-2001A patent/SK1192001A3/sk unknown
- 1999-06-02 KR KR1020017001206A patent/KR20010072089A/ko not_active Application Discontinuation
- 1999-06-02 JP JP2000562364A patent/JP2002521478A/ja active Pending
- 1999-06-02 WO PCT/US1999/012273 patent/WO2000006561A1/en not_active Application Discontinuation
- 1999-06-02 DK DK99963141T patent/DK1100792T3/da active
- 1999-06-02 CA CA002335077A patent/CA2335077A1/en not_active Abandoned
- 1999-06-02 GE GEAP19995773A patent/GEP20033052B/en unknown
- 1999-06-02 NZ NZ509439A patent/NZ509439A/xx unknown
- 1999-06-02 ID IDW20010198A patent/ID27192A/id unknown
- 1999-06-02 AU AU43292/99A patent/AU758619B2/en not_active Ceased
- 1999-06-02 AT AT99963141T patent/ATE261954T1/de not_active IP Right Cessation
- 1999-06-02 IL IL14074699A patent/IL140746A0/xx unknown
- 1999-06-02 PL PL99345776A patent/PL345776A1/xx not_active Application Discontinuation
- 1999-06-02 YU YU6701A patent/YU6701A/sh unknown
- 1999-06-02 OA OA1200100027A patent/OA11589A/en unknown
-
2001
- 2001-01-12 IS IS5810A patent/IS5810A/is unknown
- 2001-01-16 ZA ZA200100455A patent/ZA200100455B/en unknown
- 2001-01-25 BG BG105185A patent/BG105185A/xx unknown
- 2001-01-29 NO NO20010479A patent/NO20010479D0/no not_active Application Discontinuation
- 2001-01-30 HR HR20010078A patent/HRP20010078A2/hr not_active Application Discontinuation
- 2001-04-10 US US09/719,027 patent/US6420408B1/en not_active Expired - Fee Related
-
2002
- 2002-03-27 US US10/108,817 patent/US6492422B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200100455B (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases. | |
| US6350885B1 (en) | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases | |
| US6239288B1 (en) | Biphenyl hydroxy imino butyric acids and their derivatives for treating arthritis | |
| US6399612B1 (en) | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | |
| US6169103B1 (en) | Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | |
| US6624196B2 (en) | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases | |
| Strauss et al. | In vivo collagen turnover following experimental balloon angioplasty injury and the role of matrix metalloproteinases | |
| KR20010050798A (ko) | 말초 또는 중추 신경계 장애의 치료를 위한 매트릭스금속프로테이나제 억제제인 α-술포닐아미노 히드록삼산 | |
| US6037361A (en) | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases | |
| US6677355B1 (en) | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors | |
| AU736347B2 (en) | Compounds for and a method of inhibiting matrix metalloproteinases | |
| KR20000068414A (ko) | 매트릭스 메탈로프로테이나제 억제제 및 그의 치료적 용도 | |
| Watanabe et al. | Esculetin suppresses proteoglycan metabolism by inhibiting the production of matrix metalloproteinases in rabbit chondrocytes | |
| CZ2001302A3 (cs) | Tricyklické sulfonamidy a jejich deriváty jako inhibitory matricových metaloproteináz | |
| MXPA00012948A (en) | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases | |
| JP2006500422A (ja) | 酵素活性を阻害するためのキレート化剤の親油性ジエステル |